Lacidipine in Medical Practice in Patients With Mild to Moderate Essential Hypertension
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Lacidipine
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Fulfillment of entry criteria for the preceding yearly study
- Male or female patients aged between 20 and 85 years
- Known history of mild to moderate essential hypertension requiring drug treatment, WHO grade I to II
- Controlled blood pressure (RR diastolic ≤ 90 mm Hg or 91 - 95 mm Hg and concurrent reduction in blood pressure of at least 10 mm compared to baseline level) during treatment with lacidipine at a dose of 2 - 6 mg once a day
- Final visit of the previous yearly study (Visit 4) completed as scheduled
- Informed consent to participate in the follow-up study
Exclusion Criteria:
- Violation of entry/exclusion criteria on enrolment in the preceding yearly study
Occurrence of the following exclusion criteria in the intervening period:
- Pregnancy, lactation, possibility of conception without the use of a scientifically recognised method of contraception
- Secondary form of hypertension
- Consumptive illness
- Clinically manifest concomitant cardiovascular illness, e.g.: aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy or any other condition hindering left ventricular outflow, aortic isthmus stenosis, severe (NYHA Class III or higher) or decompensated heart failure, clinically relevant hypo- or hyperkinetic cardiac arrhythmia
- Myocardial infarction or cerebrovascular accident within the 6 months prior to the start of the follow-up study
- Hypersensitivity to dihydropyridines
- Concomitant long-term treatment (> 3 weeks) with antihypertensive substances not envisaged in the protocol (exception: short-acting nitrates), sedatives, tricyclic antidepressants
- Suspected alcohol, narcotic or drug abuse
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Lacidipine
Arm Description
Outcomes
Primary Outcome Measures
Number of patients with rare adverse drug reactions
Change in alkaline phosphatase (AP)
Change in serum glutamic - pyruvic transaminase (SGPT)
Secondary Outcome Measures
Change in serum glutamic - oxaloacetic transaminase (SGOT)
Number of patients with abnormal changes in laboratory parameters
Changes in systolic and diastolic blood pressure
Changes in gamma glutamyl transferase (gamma-GT)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02177331
Brief Title
Lacidipine in Medical Practice in Patients With Mild to Moderate Essential Hypertension
Official Title
Lacidipine in Medical Practice: Incidence of Rare Adverse Drug Reactions During Long-term Treatment. 3rd Follow-up Study - Long-term Use in the 4th and 5th Year Treatment Years
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
June 1995 (undefined)
Primary Completion Date
January 1998 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
In order to confirm the proposed metabolic effect of lacidipine these follow-up study was to provide long-term data on its impact on liver function, glucose homoeostasis and lipid metabolism. Additionally, its adverse drug reactions and antihypertensive effects were to be studied.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
53 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Lacidipine
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Lacidipine
Primary Outcome Measure Information:
Title
Number of patients with rare adverse drug reactions
Time Frame
up to 24 months
Title
Change in alkaline phosphatase (AP)
Time Frame
up to 24 months
Title
Change in serum glutamic - pyruvic transaminase (SGPT)
Time Frame
up to 24 months
Secondary Outcome Measure Information:
Title
Change in serum glutamic - oxaloacetic transaminase (SGOT)
Time Frame
up to 24 months
Title
Number of patients with abnormal changes in laboratory parameters
Time Frame
up to 24 months
Title
Changes in systolic and diastolic blood pressure
Time Frame
up to 24 months
Title
Changes in gamma glutamyl transferase (gamma-GT)
Time Frame
up to 24 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Fulfillment of entry criteria for the preceding yearly study
Male or female patients aged between 20 and 85 years
Known history of mild to moderate essential hypertension requiring drug treatment, WHO grade I to II
Controlled blood pressure (RR diastolic ≤ 90 mm Hg or 91 - 95 mm Hg and concurrent reduction in blood pressure of at least 10 mm compared to baseline level) during treatment with lacidipine at a dose of 2 - 6 mg once a day
Final visit of the previous yearly study (Visit 4) completed as scheduled
Informed consent to participate in the follow-up study
Exclusion Criteria:
Violation of entry/exclusion criteria on enrolment in the preceding yearly study
Occurrence of the following exclusion criteria in the intervening period:
Pregnancy, lactation, possibility of conception without the use of a scientifically recognised method of contraception
Secondary form of hypertension
Consumptive illness
Clinically manifest concomitant cardiovascular illness, e.g.: aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy or any other condition hindering left ventricular outflow, aortic isthmus stenosis, severe (NYHA Class III or higher) or decompensated heart failure, clinically relevant hypo- or hyperkinetic cardiac arrhythmia
Myocardial infarction or cerebrovascular accident within the 6 months prior to the start of the follow-up study
Hypersensitivity to dihydropyridines
Concomitant long-term treatment (> 3 weeks) with antihypertensive substances not envisaged in the protocol (exception: short-acting nitrates), sedatives, tricyclic antidepressants
Suspected alcohol, narcotic or drug abuse
12. IPD Sharing Statement
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/231/231.215_U99-1368.pdf
Description
Related Info
Learn more about this trial
Lacidipine in Medical Practice in Patients With Mild to Moderate Essential Hypertension
We'll reach out to this number within 24 hrs